PDF(Pubmed)
Abstract：
LILRB4, a myeloid inhibitory receptor belonging to the family of leukocyte immunoglobulin-like receptors (LILRs/LIRs), plays a pivotal role in the regulation of immune tolerance. LILRB4 primarily mediates suppressive immune responses by transmitting inhibitory signals through immunoreceptor tyrosine-based inhibitory motifs (ITIMs). This immune checkpoint molecule has gained considerable attention due to its potent regulatory functions. Its ability to induce effector T cell dysfunction and promote T suppressor cell differentiation has been demonstrated, indicating the therapeutic potential of LILRB4 for modulating excessive immune responses, particularly in autoimmune diseases or the induction of transplant tolerance. Additionally, through intervening with LILRB4 molecules, immune system responsiveness can be adjusted, representing significant value in areas such as cancer treatment. Thus, LILRB4 has emerged as a key player in addressing autoimmune diseases, transplant tolerance induction, and other medical issues. In this review, we provide a comprehensive overview of LILRB4, encompassing its structure, expression, and ligand molecules as well as its role as a tolerance receptor. By exploring the involvement of LILRB4 in various diseases, its significance in disease progression is emphasized. Furthermore, we propose that the manipulation of LILRB4 represents a promising immunotherapeutic strategy and highlight its potential in disease prevention, treatment and diagnosis.
摘要：
LILRB4,属于白细胞免疫球蛋白样受体(LILRs/LIRs)家族的一种髓样抑制性受体,在免疫耐受的调节中起着举足轻重的作用。LILRB4主要通过经由基于免疫受体酪氨酸的抑制基序(ITIM)传递抑制信号来介导抑制性免疫应答。这种免疫检查点分子由于其有效的调节功能而获得了相当大的关注。已证明其诱导效应T细胞功能障碍和促进T抑制细胞分化的能力，表明LILRB4调节过度免疫反应的治疗潜力，特别是在自身免疫性疾病或诱导移植耐受中。此外,通过与LILRB4分子的干预，免疫系统的反应是可以调整的，在癌症治疗等领域具有重要价值。因此，LILRB4已成为解决自身免疫性疾病的关键角色，移植耐受诱导，和其他医疗问题。在这次审查中,我们提供了LILRB4的全面概述，包括其结构，表达式,和配体分子以及它作为耐受性受体的作用。通过探索LILRB4在各种疾病中的参与，强调其在疾病进展中的意义。此外，我们认为，LILRB4的操作代表了一种有前途的免疫治疗策略，并强调了其在疾病预防中的潜力，治疗和诊断。
